Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05421325Phase 2Recruiting

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

Role: lead

NCT03472690Phase 2Terminated

QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease

Role: lead

NCT02426372Phase 2Completed

Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis

Role: lead

NCT02897999Phase 1Withdrawn

Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers

Role: lead

NCT01809275Phase 1Completed

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Role: lead

NCT02256852Phase 2Completed

Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer

Role: lead

All 6 trials loaded